Revvity, Inc. (NYSE:RVTY) Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. trimmed its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 34.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,920 shares of the company's stock after selling 8,383 shares during the quarter. Simplify Asset Management Inc.'s holdings in Revvity were worth $1,777,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. EdgePoint Investment Group Inc. raised its stake in Revvity by 34.6% in the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company's stock valued at $343,108,000 after buying an additional 690,534 shares in the last quarter. Southpoint Capital Advisors LP purchased a new position in shares of Revvity in the 3rd quarter valued at about $25,550,000. Proficio Capital Partners LLC increased its holdings in shares of Revvity by 12,298.3% in the 4th quarter. Proficio Capital Partners LLC now owns 195,769 shares of the company's stock valued at $21,850,000 after acquiring an additional 194,190 shares during the last quarter. Tocqueville Asset Management L.P. raised its position in shares of Revvity by 91.2% during the 4th quarter. Tocqueville Asset Management L.P. now owns 234,625 shares of the company's stock worth $26,186,000 after acquiring an additional 111,937 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Revvity by 1.7% during the third quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company's stock worth $809,332,000 after purchasing an additional 108,401 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company's stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tajinder S. Vohra sold 5,492 shares of the firm's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares of the company's stock, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. 0.68% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on RVTY. Raymond James reiterated an "outperform" rating and issued a $145.00 price target (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Sanford C. Bernstein downgraded shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective for the company. in a research note on Friday, January 10th. Barclays upped their target price on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target on the stock in a research report on Friday, December 13th. Finally, KeyCorp increased their price objective on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $136.25.

Revvity Stock Performance

NYSE:RVTY traded up $0.05 during mid-day trading on Thursday, reaching $107.41. The stock had a trading volume of 614,018 shares, compared to its average volume of 848,618. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The business has a 50 day simple moving average of $115.42 and a 200 day simple moving average of $117.28. Revvity, Inc. has a twelve month low of $97.32 and a twelve month high of $129.50. The firm has a market capitalization of $12.90 billion, a price-to-earnings ratio of 48.60, a PEG ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the prior year, the firm earned $1.25 EPS. On average, analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio (DPR) is 12.67%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.